美国Endo Pharmaceuticals Endo Health Solutions   
Endo药物公司成立于1997年,是一家专业制药公司的研究，开发，销售和品牌和非专利处方药，用于治疗和管理的疼痛，膀胱癌，前列腺癌和青春期的儿童，或中枢性性早熟（人民党早发从事药品营销）。其产品包括LIDODERM（R）的一个专题片，以减轻疼痛的带状疱疹后遗神经痛;波拷赛特（R）和Percodan（注册商标）为中度至重度疼痛片;弗罗瓦（R）用于治疗急性粒偏头痛的攻击或无成人先兆; OPANA（R）的片用于中度至重度急性疼痛的阿片类药物如使用适当的救济; OPANA（R）的急诊室为救济片中度至重度疼痛患者需要一个较长时期的持续，大约24小时阿片类药物治疗;扶他林（R）的凝胶，它是由诺华公司拥有，非类固醇消炎药物对骨关节炎疼痛表示许可关节经得起局部治疗，如手和膝盖的活动;为晚期前列腺癌的姑息治疗VANTAS（注册商标）; SUPPRELIN（R）的洛杉矶为在青春期儿童的早期发病治疗;及瓦尔斯塔尔（商标）卡介苗为难治性原位癌的患者膀胱（独联体）治疗膀胱切除术的人立即将与不可接受的医疗风险有关。该公司销售其品牌产品在痛苦中医药管理，泌尿，内分泌学，肿瘤学，神经病学，外科和初级保健医生。


Endo Pharmaceuticals is a specialty pharmaceutical company engaged in the research, development, sale and marketing of branded and generic prescription pharmaceuticals used to treat and manage pain, bladder cancer, prostate cancer and the early onset of puberty in children, or central precocious puberty (CPP). Its products include LIDODERM®, a topical patch to relieve the pain of postherpetic neuralgia; Percocet® and Percodan® tablets for the relief of moderate-to-moderately severe pain; FROVA® tablets for the acute treatment of migraine attacks with or without aura in adults; OPANA® tablets for the relief of moderate-to-severe acute pain where the use of an opioid is appropriate; OPANA® ER tablets for the relief of moderate-to-severe pain in patients requiring continuous, around-the-clock opioid treatment for an extended period of time; Voltaren® Gel, which is owned and licensed by Novartis AG, a nonsteroidal anti-inflammatory drug indicated for the relief of the pain of osteoarthritis of joints amenable to topical treatment, such as those of the hands and the knees; VANTAS® for the palliative treatment of advanced prostate cancer; SUPPRELIN® LA for the treatment of early onset puberty in children; and VALSTAR™ for the treatment of BCG-refractory carcinoma in situ (CIS) of the urinary bladder in patients for whom immediate cystectomy would be associated with unacceptable medical risks. The company markets its branded pharmaceutical products to physicians in pain management, urology, endocrinology, oncology, neurology, surgery and primary care.

Endo was established in 1997 through a management buyout from DuPont Merck. The company is based in Chadds Ford, PA and employs more than 1,200 employees throughout the U.S.